Quinazolinone Compounds Targeting Mitochondrial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mitochondrial dysfunction is associated with a wide range of human diseases, including cancer, neurodegenerative diseases, and non-neurological disorders, due to impaired cellular energy production, oxidative stress, altered calcium homeostasis, and dysregulated cell death pathways.
Innovation Solution
Development of quinazolinone compounds and their pharmaceutically acceptable salts, which can be administered to target mitochondrial dysfunction, thereby treating associated diseases by improving cellular energy, reducing oxidative stress, and modulating calcium homeostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for mitochondrial dysfunction, then some symptoms may be addressed, but the underlying mitochondrial defects remain uncorrected and disease progression continues
Solution Approach 1:
The patent employs mitochondrial-targeted compounds (such as mitochondria-targeted antioxidants like MitoQ, mitochondrial uncouplers like DNP derivatives, and mitochondrial membrane potential modulators) as intermediaries to deliver therapeutic effects directly to mitochondria. These compounds contain lipophilic cations or other targeting moieties that facilitate accumulation in mitochondria, enabling selective modulation of mitochondrial function without requiring complex systemic interventions.
Solution Approach 2:
The invention utilizes compounds that modulate key mitochondrial parameters including membrane potential (ΔΨm), reactive oxygen species production, ATP synthesis rate, and calcium handling. By changing these physiological parameters through pharmacological intervention, the patent restores mitochondrial function to a therapeutic range, addressing the root cause rather than just symptoms.
2Use of energy by moving object
If mitochondrial function is enhanced to treat disease, then cellular energy production improves, but oxidative stress and ROS production may increase
Solution Approach 1:
The patent employs compounds that dynamically regulate mitochondrial function rather than providing static enhancement. Mitochondrial uncouplers create a dynamic balance between ATP production and heat generation, while modulators of electron transport chain complexes provide reversible, titratable control over oxidative phosphorylation rate. This dynamic approach allows the system to adapt and maintain ROS levels within acceptable ranges while enhancing energy production.
Solution Approach 2:
The invention converts the harmful effect of ROS into a beneficial signaling mechanism by using low levels of ROS generated during enhanced mitochondrial function to activate protective pathways (such as Nrf2, NF-κB, or HIF-1α). Additionally, mitochondria-targeted antioxidants are designed to selectively scavenge excessive ROS while permitting physiological levels to maintain their signaling functions, thus converting the potential harm into a therapeutic advantage.
Data Source
AI summary
New quinazolinone compounds are disclosed, as well as pharmaceutical compositions containing quinazolinones and methods for the treatment of diseases and conditions associated with mitochondrial dysfunction.